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The goal of this study was to investigate the association between gout and Parkinson’s disease in older
people in Taiwan. Utilizing the Taiwan National Health Insurance database, this caseecontrol study
included 3854 patients aged 65 years or older with newly diagnosed Parkinson’s disease as the case
group [mean age 75.0 years and standard deviation (SD) 5.0 years], and 15,416 patients without Par-
kinson’s disease as the control group (mean age 74.0 years and SD 5.3 years). Multivariable logistic
regression analysis detected no association between gout and Parkinson’s disease in both sex [odds ratio
(OR) ¼ 0.98, 95% conﬁdence interval (CI) ¼ 0.86e1.12, in men and OR ¼ 1.03, 95% CI ¼ 0.88e1.21, in
women, respectively]. We conclude that no association can be detected between gout and Parkinson’s
disease in older people in Taiwan.
Copyright  2013, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.In order to investigate the association between gout and Par-
kinson’s disease in older people in Taiwan, we conducted this casee
control study utilizing the Taiwan National Health Insurance
database. The details of insurance program can be found in pre-
vious studies1,2. The present study included 3854 patients aged 65
years or older with newly diagnosed Parkinson’s disease as the case
group [1994 men and 1860 women, mean age 75.0 years and
standard deviation (SD) 5.0 years] (based on the International
Classiﬁcation of Diseases, 9th Revision, Clinical Modiﬁcation, ICD-9
332), and 15,416 patients without Parkinson’s disease as the control
group (7976men and 7440 women, mean age 74.0 years and SD 5.3
years). Both groups were matched by age, sex, and index date in the
database from 2000 to 2010. The index datewas deﬁned as the date
of cases diagnosed with Parkinson’s disease. Gout was diagnosed
before the diagnosis of Parkinson’s disease based on ICD-9 274. We
analyzed the data separately by sex. Patients with other major
psychiatric diseases (ICD-9 291e293, 294.0, 294.8, 294.9, 295,
296.0, 296.1, 296.4e296.9, 297 and 298), mental retardation (ICD-9Internal Medicine, Taichung
, Tanzi District, Taichung City
iao).
iwan Society of Geriatric Emergen317e319), and only diagnosis of hyperuricemia (ICD-9 790.61) but
without gouty attack (ICD-9 274) were excluded from this study.
Table 1 shows the basic characteristics between Parkinson’s
disease cases and controls. In men, there were 488 patients with
gout among Parkinson’s disease cases (24.5%) and 1673 patients
with gout among control patients (21.0%) (p ¼ 0.0007). In women,
there were 280 patients with gout among Parkinson’s disease cases
(15.1%) and 850 patients with gout among control patients (11.4%)
(p < 0.0001). After controlling for covariates that were signiﬁcantly
related to Parkinson disease in the crude analysis, multivariable
logistic regression analysis showed that no association could be
detected between gout and Parkinson’s disease in both sexes [odds
ratio (OR) ¼ 0.98, 95% conﬁdence interval (CI) ¼ 0.86e1.12, in men
and OR ¼ 1.03, 95% CI ¼ 0.88e1.21, in women, respectively]
(Table 2). As a reference of non-gout group, the further analysis
stratiﬁed by anti-gout therapy or not also showed that no associ-
ation could be detected between gout and Parkinson’s disease, no
matter whether the patients received anti-gout therapy or not (data
not shown).
Recent studies have shown strong evidence that there is an
inverse association of serum uric acid or gout with Parkinson’s
disease risk3e5. That is, individuals with hyperuricemia or gout may
have lower risk of Parkinson’s disease. Moreover, the evidence has
shown that oxidative stress might be involved in Parkinson’scy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Basic characteristics between Parkinson’s disease cases and controls.
Men Women
Parkinson’s disease p Parkinson’s disease p
No Yes No Yes
n ¼ 7976 n ¼ 1994 n ¼ 7440 n ¼ 1860
n (%) n (%) n (%) n (%)
Mean age (SD) (y)a 74.4 5.24 75.4 4.91 <0.0001 73.5 5.36 74.5 5.05 <0.0001
Co-morbidities before index datec
Gout 1673 21.0 488 24.5 0.0007 850 11.4 280 15.1 <0.0001
Obesityb 13 0.16 2 0.10 0.52 29 0.39 11 0.59 0.23
Diabetes mellitus 1973 24.7 643 32.3 <0.0001 2213 29.7 803 43.2 <0.0001
Hyperlipidemia 1691 21.2 505 25.3 <0.0001 2229 30.0 670 36.0 <0.0001
Hypertension 5050 63.3 1589 79.7 <0.0001 5093 68.5 1556 83.7 <0.0001
Cerebrovascular disease 1946 24.4 1213 60.8 <0.0001 1814 24.4 1024 55.1 <0.0001
Dementia 170 2.13 296 14.8 <0.0001 173 2.33 263 14.1 <0.0001
Major depressive disorder 332 4.16 233 11.7 < 0.0001 455 6.12 338 18.2 <0.0001
Chronic kidney disease 447 5.60 173 8.68 <0.0001 275 3.70 124 6.67 <0.0001
Head injury 277 3.47 132 6.62 <0.0001 247 3.32 116 6.24 <0.0001
Tobacco useb 43 0.54 14 0.70 0.39 5 0.07 0 0.00 0.59
Alcoholismb 22 0.28 11 0.55 0.06 0 0.00 1 0.05 0.2
Polypharmacy 1749 21.9 819 41.1 <0.0001 1564 21.0 770 41.4 <0.0001
Data are presented as the number of patients in each group, with percentages given in parentheses.
Chi-square test, b Fisher’s exact test and a t test comparing patients with and without Parkinson’s disease.
c The co-morbidities included before index date were as follows: gout (ICD-9 274), obesity (ICD-9 278.00 and 278.01), diabetes mellitus (ICD-9 250), hyperlipidemia (ICD-9
272.0, 272.1, 272.2, 272.3 and 272.4), hypertension (ICD-9 401-405), cerebrovascular disease (ICD-9 430e438), dementia (ICD-9 290.0, 290.1, 290.2, 290.3, 290.4, 294.1 and
331.0), major depressive disorder (ICD-9 296.2, 296.3, 300.4 and 311), chronic kidney disease (ICD-9 585, 586, 588.8 and 588.9), head injury (ICD-9 850-854 and 959.01),
tobacco use (ICD-9 305.1) and alcoholism (ICD-9 303, 305.00, 305.01, 305.02, 305.03 and V11.3). Polypharmacy was deﬁned as the daily average use of ﬁve or more drugs.
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uric acid or gout can be partially explained by the mechanism that
uric acid has an antioxidant effect which could reduce oxidative
stress and it might further delay the progression of Parkinson’s
disease7e9. A cohort study by De Vera et al in Canada has shown
that patients with gout have lower risk of Parkinson’s disease
compared with patients without gout (relative risk 0.70, 95% CI
0.59e0.83)4. However, in the present study, we detected no asso-
ciation between gout and Parkinson’s disease in either sex. In fur-
ther analysis, no association could be detected between anti-gout
therapy and Parkinson’s disease. Because this is only an observa-
tional study, we can not make a plausible explanation about the
above different results. Moreover, population-selected and meth-
odological characteristics may partially account for the conﬂicting
results between this and other studies. Therefore, more prospective
studies are needed to elucidate this issue.
Some potential bias should be mentioned. First, since this
database had no record of serum uric acid levels. It would be pos-
sible to underestimate the prevalence of hyperuricemia. Second,
the ICD-9 332 includes Parkinson’s disease and secondary parkin-
sonism. It would be possible to overestimate the prevalence of
Parkinson’s disease. Third, in addition to anti-gout drugs, someTable 2
Odds ratios and 95% conﬁdence intervals of Parkinson’s disease associated with
gout.
Variable Men Women
Crude Adjusteda Crude Adjusteda
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Gout (yes
vs. no)
1.22 (1.09,
1.37)
0.98 (0.86,
1.12)
1.37 (1.19,
1.59)
1.03 (0.88,
1.21)
CI ¼ conﬁdence interval; OR ¼ odds ratio.
a Adjusted OR in both sexes: adjusted for age, diabetes mellitus, hyperlipidemia,
hypertension, cerebrovascular disease, dementia, major depressive disorder,
chronic kidney disease, head injury, and polypharmacy.anti-parkinsonian drugs may also inﬂuence serum uric acid levels.
Fourth, because of the time lag between index date of diagnosing
Parkinson’s disease and onset of Parkinson’s disease, we could not
ascertain whether a gout attack was before or after onset of Par-
kinson’s disease.
We conclude that no association can be detected between gout
and Parkinson’s disease in older people in Taiwan.Acknowledgments
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